NasdaqCM:PLSEMedical Equipment
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?
Pulse Biosciences, Inc. recently shifted its capital allocation to prioritize and accelerate development of its nPulse Cardiac Catheter Ablation System after reporting strong European feasibility data in atrial fibrillation patients, while scaling back near-term spending in cardiac surgery and soft-tissue ablation programs.
The move effectively concentrates the company’s resources on a single electrophysiology platform that early data suggest may offer an unusual mix of speed, safety and...